MapLight Therapeutics to Participate in Upcoming Investor Conferences
Friday, May 8, 2026 1 min read
Key Takeaway: MapLight Therapeutics, Inc. announced its participation in two upcoming investor conferences: the 2026 RBCCM Global Healthcare Conference on May 19 and the 2026 Jefferies Global Healthcare Conference on June 3. The management team will present and host one-on-one meetings at both events. The company aims to improve treatments for central nervous system disorders.
Conference Participation Details
Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat
How to Access
Investors and the general public can listen to both sessions live at:
Archived versions will be available following the live events for a limited time.
Market Sentiment Analysis
POSITIVE FACTORS
Participation in notable investor conferences enhances visibility.
Management team's engagement indicates confidence in company prospects.
Focus on central nervous system disorders highlights a critical area of need.
Full Press Release Details
SAN FRANCISCO and BOSTON, May 08, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conferences:
Event: 2026 RBCCM Global Healthcare Conference (New York, NY)Date: Tuesday, May 19thFormat: Presenting and hosting 1x1 meetings
Event: 2026 Jefferies Global Healthcare Conference (New York, NY)Date: Wednesday, June 3rdFormat: Presenting and hosting 1x1 meetings
Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the “Events & Presentations” page on the Investor section of the company’s website athttps://ir.maplightrx.com/news-events/events-presentations.
About MapLight Therapeutics
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The Company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The Company’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. For more information, please visitwww.maplightrx.com.